If your business touches compounded peptides, one FDA list matters more than most of the commentary written about the category: the interim policy's category 2, the substances FDA says "may present significant safety risks" in compounding. Many of the best-known names in the peptide market sit on it. This article explains the framework in the agency's own words, because what FDA actually says is more useful, and usually more careful, than what gets repeated about it.
The framework in two paragraphs
Compounding is the preparation of drug products outside the standard approval path, under sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act. Section 503A covers traditional pharmacy compounding; 503B covers larger outsourcing facilities. For each, FDA is building a list of bulk drug substances that may lawfully be used. While those lists are developed, an interim policy, finalized in January 2025, sorts nominated substances into three categories.
Category 1 substances were nominated with enough supporting information to evaluate and may be used while review continues. Category 3 substances were nominated without sufficient support. Category 2 is the one that matters here. In FDA's words: "Bulk drug substances that may present significant safety risks have been placed in category 2 under the interim policies."
Which peptides are in category 2
FDA publishes the category 2 list on a page titled Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks, with a stated rationale per substance. The peptides on it include BPC-157, ipamorelin, CJC-1295, AOD-9604, epitalon, selank, semax, dihexa, melanotan, kisspeptin, and entries from the thymosin and GHRP families. Each carries FDA's specific concern in a sentence or two.
The BPC-157 entry is worth reading verbatim, because it shows how the agency reasons: "Compounded drugs containing BPC-157 may pose risk for immunogenicity for certain routes of administration and may have complexities with regard to peptide-related impurities and active pharmaceutical ingredient (API) characterization. FDA has identified no, or only limited, safety-related information for the proposed routes of administration." Note what that is and is not. It is a statement about missing safety information and manufacturing complexity, made in a regulatory screening context. We quote it because the exact character of FDA's concern is something your compliance posture, and your content, should represent accurately rather than paraphrase into something stronger or weaker.
What category 2 means, and what it does not
It means FDA identified potential significant safety risks when it reviewed the substance's nomination, and that the substance is not on the permitted bulks list. Under the interim policy, that placement signals FDA's enforcement posture toward compounding with it.
It does not make a substance a controlled substance, and it is not a final determination for all time. The process is live: FDA's Pharmacy Compounding Advisory Committee met on July 23 and 24, 2026 to discuss substances being considered for the 503A bulks list, including BPC-157 free base and BPC-157 acetate. Categories can change as the agency works through nominations, which is exactly why content that hard-codes yesterday's status without a date becomes a liability.
Why a marketing company is writing about this at all
Because in this vertical, regulatory precision is a marketing asset and imprecision is a marketing risk. Three specific reasons:
- Ad platforms key off regulatory action. Google's policy reaches products "subject to any government or regulatory action or warning", so the compounding lists are part of your advertising eligibility picture, not just your legal one.
- Content claims get judged against the record. A clinic or brand whose pages contradict what FDA has published about a substance is handing both regulators and competitors an easy finding.
- Search quality systems reward sourced accuracy. Health-adjacent content is held to Google's highest standard, and citing the primary record, with dates, is how a site earns trust in a category full of sites that do not.
The usual disclaimer applies doubly here: we are a search marketing firm, not your counsel, and nothing on this page is legal advice. What we bring is the discipline of writing about the regulatory record exactly as it stands, which is the same discipline your own content needs if it is going to survive scrutiny from platforms, regulators, and the search systems that decide whether anyone finds you.
Frequently asked questions
What is category 2 in FDA's compounding policy?
Under FDA's interim policy for compounding with bulk drug substances, category 2 holds substances that FDA says may present significant safety risks, identified while reviewing their nominations for the 503A and 503B bulks lists. Placement reflects FDA's screening judgment and enforcement posture during the interim period, not a final determination.
Is BPC-157 on an FDA risk list?
Yes. FDA's page on bulk drug substances that may present significant safety risks includes BPC-157, citing possible immunogenicity risk for certain routes of administration, complexities with peptide-related impurities and API characterization, and limited safety-related information for the proposed routes. FDA's advisory committee also discussed BPC-157 substances for the 503A bulks list in July 2026.
Does category 2 mean a peptide is a controlled substance?
No. The compounding categories are about which bulk ingredients may be used in compounded drug products while FDA develops its permitted lists. Scheduling under the Controlled Substances Act is a separate legal framework. The categories can also change as FDA works through nominations, which is why any statement about a substance's status needs a date on it.
Why does FDA's compounding list matter for peptide marketing?
Because ad platforms and search systems both key off the regulatory record. Google's ads policy reaches products subject to government action or warning, and health-adjacent content is judged by Google's strictest quality standards. Content that represents the record precisely, with citations and dates, performs better and carries less risk than content that paraphrases it loosely.
